

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No equalities issues raised at scoping |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| It was noted in the company submission that black ethnic groups have substantially higher mortality rates for endometrial cancer mortality than other ethnic groups in the UK. The company said access to innovative treatment on the NHS for late-stage disease can help address severe inequalities in survival outcomes by ethnicity or socio-economic deprivation. |

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

None identified

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, in section 3.16.

Approved by Associate Director (name): ...Janet Robertson.....

Date: 30 January 2024

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Issue date: February 2024